Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029431 | 1.00 | CHRM2 (0.47) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL12093218 | 0.88 | CHRM2 (0.48) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL12093217 | 0.87 | GPR119 (0.47) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL12094659 | 0.86 | CHRM2 (0.46) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL12094724 | 0.85 | GPR119 (0.46) | CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL14873083 | 0.84 | GPR119 (0.55) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL6758133 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL6761176 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL20989367 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP | |
| SCHEMBL6758129 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3GPR119PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957493-B1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | ORGANON NV (NL) | 2011-01-19 | — | — | EP | disclosed |
| US-7605170-B2 | 8-azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2009-10-20 | — | — | US | disclosed |
| EP-1957493-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-08-20 | — | — | EP | disclosed |
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | N.V. ORGANON (NL) | 2007-08-09 | — | — | US | disclosed |
| WO-2007063071-A1 | 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185156-A1 | 8-Azabicyclo[3.2.1]octane derivatives | SLC22A8, SLCO1B3, SLCO1B1 | CHRM2 1718/4885CHRM1 1961/4885CHRM3 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.